Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Synthesis of (aminoalkylamine)-N-aminoalkyl)azanonaborane(11) derivatives for boron neutron capture therapy.

Authors:
Mohamed E El-Zaria Udo Dörfler Detlef Gabel

J Med Chem 2002 Dec;45(26):5817-9

Department of Chemistry, University of Bremen, P.O. Box 330440, D-28334 Bremen, Germany.

New boron-containing polyamine have been synthesized: (aminoalkylamine)-N-(aminoalkyl)azanonaborane(11) derivatives [H(2)N(CH(2))(n)H(2)NB(8)H(11)NH(CH(2))(n)NH(2)], where n = 4-6 and 12, and [H(2)N(CH(2))(3)H(2)NB(8)H(11)NH(CH(2))(4)NH(2)]. (4-Aminobutylamine)-N-(4-aminobutyl)azanonaborane and (3-aminopropylamine)-N-(4-aminobutyl)azanonaborane were less toxic in vitro (LD(50) of approximately 700 and approximately 1100 microM, respectively) than spermine, while (4-aminobutylamine)-N-isopropylazanonaborane with its hydrophobic isopropyl group and those with n = 5, 6, and 12 were already toxic under similar conditions (LD(50) < 500 microM). These compounds may be useful as delivery agents for boron neutron capture therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm020971kDOI Listing
December 2002

Publication Analysis

Top Keywords

neutron capture
8
boron neutron
8
aminoalkylamine-n-aminoalkylazanonaborane11 derivatives
8
capture therapy
8
4-aminobutylamine-n-4-aminobutylazanonaborane 3-aminopropylamine-n-4-aminobutylazanonaborane
4
3-aminopropylamine-n-4-aminobutylazanonaborane toxic
4
isopropyl group
4
ld50 500
4
hydrophobic isopropyl
4
4-6 [h2nch23h2nb8h11nhch24nh2]
4
500 microm
4
[h2nch23h2nb8h11nhch24nh2] 4-aminobutylamine-n-4-aminobutylazanonaborane
4
toxic vitro
4
conditions ld50
4
1100 microm
4
spermine 4-aminobutylamine-n-isopropylazanonaborane
4
microm spermine
4
700 1100
4
toxic conditions
4
[h2nch2nh2nb8h11nhch2nnh2] 4-6
4

Keyword Occurance

Similar Publications

Correction: The potential role of borophene as a radiosensitizer in boron neutron capture therapy (BNCT) and particle therapy (PT).

Authors:
Pengyuan Qi Qianyuan Chen Dong Tu Songhuan Yao Yupeng Zhang Jike Wang Conghua Xie Chunxu Pan Hao Peng

Biomater Sci 2021 Apr 26;9(7):2743-2744. Epub 2021 Mar 26.

Department of Medical Physics, Wuhan University, Luojiashan Rd, 430072 China.

Correction for 'The potential role of borophene as a radiosensitizer in boron neutron capture therapy (BNCT) and particle therapy (PT)' by Pengyuan Qi et al., Biomater. Sci. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Neutron flux evaluation model provided in the accelerator-based boron neutron capture therapy system employing a solid-state lithium target.

Authors:
Satoshi Nakamura Hiroshi Igaki Masashi Ito Shoji Imamichi Tairo Kashihara Hiroyuki Okamoto Shie Nishioka Kotaro Iijima Takahito Chiba Hiroki Nakayama Mihiro Takemori Yoshihisa Abe Tomoya Kaneda Kana Takahashi Koji Inaba Kae Okuma Naoya Murakami Yuko Nakayama Mitsuko Masutani Teiji Nishio Jun Itami

Sci Rep 2021 Apr 13;11(1):8090. Epub 2021 Apr 13.

Division of Research and Development for Boron Neutron Capture Therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.

An accelerator-based boron neutron capture therapy (BNCT) system employing a solid-state Li target can achieve sufficient neutron flux for treatment although the neutron flux is reduced over the lifetime of its target. In this study, the reduction was examined in the five targets, and a model was then established to represent the neutron flux. In each target, a reduction in neutron flux was observed based on the integrated proton charge on the target, and its reduction reached 28% after the integrated proton charge of 2. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Optimized beam shaping assembly for a 2.1-MeV proton-accelerator-based neutron source for boron neutron capture therapy.

Authors:
Pablo Torres-Sánchez Ignacio Porras Nataliya Ramos-Chernenko Fernando Arias de Saavedra Javier Praena

Sci Rep 2021 Apr 7;11(1):7576. Epub 2021 Apr 7.

Departamento de Física Atómica, Molecular y Nuclear, Facultad de Ciencias, Universidad de Granada, 18071, Granada, Spain.

Boron Neutron Capture Therapy (BNCT) is facing a new era where different projects based on accelerators instead of reactors are under development. The new facilities can be placed at hospitals and will increase the number of clinical trials. The therapeutic effect of BNCT can be improved if a optimized epithermal neutron spectrum is obtained, for which the beam shape assembly is a key ingredient. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Interactions of an Imine Polymer with Nanoporous Silica and Carbon in Hybrid Adsorbents for Carbon Capture.

Authors:
Gernot Rother Uma Tumuluri Kuan Huang William T Heller Sheng Dai Jan-Michael Carrillo Bobby G Sumpter

Langmuir 2021 Apr 5;37(15):4622-4631. Epub 2021 Apr 5.

Center for Nanophase Materials Sciences, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, United States.

Efficient carbon capture from stationary point sources can be achieved using hybrid adsorbents comprising nanoporous substrates coated with imine polymers. The physical properties of the CO-adsorbing, nanodispersed polymers are altered by their interactions with the substrate, which in turn may impact their capture capacity. We study silica and carbon nanoporous substrates with different pore morphologies that were impregnated with polymer imine with the goal of characterizing the polymer dispersions in the pores. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

The 35th Anniversary of the Discovery of EPR Effect: A New Wave of Nanomedicines for Tumor-Targeted Drug Delivery-Personal Remarks and Future Prospects.

Authors:
Hiroshi Maeda

J Pers Med 2021 Mar 22;11(3). Epub 2021 Mar 22.

BioDynamics Research Foundation, Kumamoto 862-0954, Japan.

This Special Issue on the enhanced permeability and retention (EPR) effect commemorates the 35th anniversary of its discovery, the original 1986 Matsumura and Maeda finding being published in as a new concept in cancer chemotherapy. My review here describes the history and heterogeneity of the EPR effect, which involves defective tumor blood vessels and blood flow. We reported that restoring obstructed tumor blood flow overcomes impaired drug delivery, leading to improved EPR effects. Read More

View Article and Full-Text PDF
March 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap